A2 milk review links indigenous cattle genetics to premium rural dairy markets

A review published in Dairy Science and Management examines how milk from cows carrying the A2A2 β-casein genotype could serve as a high-value agricultural product for rural economies, particularly in the Global South. The authors, led by Hasitha Priyashantha and Janak K. Vidanarachchi, synthesize current scientific evidence, market data, and policy discussions on A2 milk’s biochemical basis, its contested health benefits, and the socioeconomic opportunities of producing it through smallholder and cooperative dairy systems. The review was published on 30 September 2025 as an open-access article.

The biochemical distinction between the two β-casein variants is small but consequential. Bovine milk contains roughly 3.5% protein, about 80% of which is casein, and β-casein alone accounts for an estimated 30% of total protein in cow’s milk. The A1 and A2 genetic variants differ at a single amino acid position: position 67 carries histidine in A1 β-casein and proline in A2 β-casein. This structural difference influences digestion, because A1 milk releases higher levels of β-casomorphin-7 (BCM-7), a peptide with opioid-like properties observed in vitro, during digestion. A2 milk, with its proline structure, releases significantly less BCM-7, reducing its potential absorption. The polymorphism also alters protein hydrophobicity, micelle formation, and secondary structure, with A1 milk showing greater β-turn and α-helix structures while A2 milk features more random or polyproline II structures.

Beyond the casein variant, the review notes reported compositional differences, including smaller fat globules and higher polyunsaturated fatty acid content in A2 milk, and higher calcium and phosphorus levels in A1 milk. One study cited found A2 milk contained lower saturated fatty acids and higher monounsaturated fatty acids than A1 milk. These differences matter commercially: A1 milk shows superior rennet and acid coagulation properties, yielding firmer curds and shorter coagulation times that favor cheese production, whereas A2 milk’s poorer coagulation produces looser curds and lower cheese yields, particularly when A2 β-casein content exceeds 50%. Conversely, A2 milk’s smaller fat globules and enhanced emulsifying and foaming capabilities suit it to products like yogurt, where creaming stability is beneficial.

The health evidence remains the review’s most cautious territory. Current support for A2 milk’s benefits is limited primarily to gastrointestinal tolerance. Two systematic reviews cited concluded that A1 β-casein consumption is associated only with increased gastrointestinal transit time and mild digestive symptoms in some individuals, with no established links to chronic diseases. In randomized cross-over trials, individuals with self-reported lactose intolerance experienced reduced post-dairy discomfort when consuming A2 milk, but these studies relied on self-reported symptoms rather than objective biomarkers, and recent analytical work confirms A2 milk still produces measurable BCM-7, albeit in lower quantities. Claims linking A1 β-casein to cardiovascular disease and type 1 diabetes lack reliable evidence, and the European Food Safety Authority concluded in 2009 that evidence did not support a cause-and-effect relationship between BCM-7 and neurological function. The clinical significance of BCM-7 observations, including reported high serum levels in infants with developmental delays, remains uncertain.

Commercially, however, the market is expanding rapidly. The global A2 milk market was valued at USD 4.0 billion in 2024 and is projected to grow at a compound annual rate of 18.5% through 2030, driven by rising health consciousness, the prevalence of lactose intolerance, and demand for functional foods. Consumer studies across regions indicate willingness to pay premiums for A2 milk based on perceived health benefits. Italian consumers with heightened awareness of food quality showed significant willingness to pay more, particularly in health-conscious segments, while a study in Hyderabad, India found middle-aged, educated, higher-income consumers sought A2 milk for perceived benefits including improved brain function, with product quality, accessibility, and word-of-mouth as key purchase drivers. High costs and limited awareness persist as barriers, and the review stresses that high production costs and unpredictable financial returns necessitate conservative approaches.

The genetic foundation of A2 production lies disproportionately in indigenous and non-bovine breeds. Jersey cows showed an A2 allele frequency of 0.94 in some populations, and Indian breeds including Gir, Sahiwal, Red Sindhi, Tharparkar, and Kangayam are frequently cited for predominantly A2 status. In Sri Lanka, indigenous Thamankaduwa White cattle exhibit an A2A2 genotype frequency of 0.82 with an A2 allele frequency of 0.91, compared to 0.61 in Holstein Friesian and 0.48 in Ayrshire, and local white cattle from Thamankaduwa and Kinniya showed exclusively the A2A2 genotype in a recent study. Among non-bovine species, genotyping of 657 water buffaloes across four breeds revealed exclusive A2A2 homozygosity, confirming all buffalo milk is naturally A2 without selective breeding, while Egyptian goats and sheep showed A2 allele frequencies of 0.56 and 0.57 respectively, higher than cattle’s A1 prevalence of 0.54. Leveraging these breeds also supports conservation of genetic diversity threatened by crossbreeding programs.

On sustainability, the review connects A2 production with regenerative agriculture practices. Adaptive multi-paddock grazing has demonstrated improvements in soil organic carbon of 13%, equivalent to 9 megagrams of carbon per hectare, and nitrogen content of 9%, or 1 megagram of nitrogen per hectare, over conventional systems. Region-specific examples include Sri Lankan Thamankaduwa White cattle adapted to tropical climates within semi-intensive systems representing 72.7% of farms, and Indian Sahiwal cattle contributing to soil microbial diversity improvements of 25% through rotational grazing in mixed crop-livestock systems supporting approximately 70% of dairy farmers. The authors frame these figures as illustrative of synergy between A2 milk production and regenerative frameworks rather than as proven outcomes of A2 adoption itself.

For smallholder farmers, who dominate milk production in South Asia, the review argues that cooperatives are the critical vehicle for capturing A2 premiums. Smallholders face low productivity, limited market access, price fluctuations, and weak negotiation power, and collective action through dairy cooperatives can provide veterinary services, artificial insemination with A2 genetics, feed supplies, quality control, chilling and processing infrastructure, and bargaining power with larger processors. India’s Amul cooperative is cited as the exemplar of how collective action transformed a dairy sector. Value-added processing of A2 milk into specialized yogurts, cheeses, ghee, butter, or infant formula ingredients could capture more of the final product’s value in rural areas, generating off-farm employment. The authors caution, however, that economic feasibility depends on continued consumer preference, strong farmer organization, appropriate policies, infrastructure investment, and fair value-chain governance ensuring farmers are not exploited by intermediaries.

Substantial obstacles temper the outlook. Regulatory standardization is weak, with 60% of countries having no specific guidelines for labelling β-casein variants and only 10% of dairy markets having robust methods to verify A2 purity. Testing technologies show promise but remain inconsistent: locked nucleic acid probes achieve 95% accuracy in detecting A1/A2 alleles but are costly, Fourier transform infrared spectroscopy distinguishes the variants with 90% accuracy but at small sample sizes, and liquid chromatography-mass spectrometry methods face reproducibility variability of 5 to 9%. Supply chain segregation adds further burden, requiring dedicated tankers, processing lines, strict cleaning programs, and accredited laboratory testing at farm gate, plant arrival, and final product stages to prevent A1 cross-contamination, with cold chain infrastructure a particular challenge in developing countries. The review concludes that A2 milk should complement, not replace, conventional dairy systems, and that independent large-scale clinical trials, harmonized certification standards, and supportive policies are needed before its promised rural transformation can be realized.

Subject of Research: Health, market, and sustainability dimensions of A2 β-casein milk production in rural dairy systems

Article Title: Role of A2 milk in rural transformations: Health benefits, market potential, and sustainable production pathways

Article References: Priyashantha, H., Jayathissa, I. S., Jayarathna, S., Senaratna, D., Narayana, N., & Vidanarachchi, J. K. (2025). Role of A2 milk in rural transformations: Health benefits, market potential, and sustainable production pathways. Dairy Science and Management, 2(1), Article 11. https://doi.org/10.1186/s44363-025-00013-x

Image Credits: AI Generated

DOI: 10.1186/s44363-025-00013-x

Keywords: A2 milk, β-casein, BCM-7, dairy cooperatives, indigenous cattle, smallholder farming, regenerative agriculture, functional foods, lactose intolerance, Global South, market growth, food certification